Log in
Enquire now
‌

US Patent 10465006 Humanized or chimeric CD3 antibodies

Patent 10465006 was granted and assigned to Genmab A/S on November, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
‌
Genmab A/S
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10465006
Date of Patent
November 5, 2019
Patent Application Number
14902757
Date Filed
July 4, 2014
Patent Citations Received
‌
US Patent 11970544 Antibodies
0
‌
US Patent 11359015 Humanized or chimeric CD3 antibodies
‌
US Patent 11858995 Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
0
‌
US Patent 11485796 Inert format
‌
US Patent 11535679 Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
‌
US Patent 11548952 Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
‌
US Patent 11008399 Antibodies
‌
US Patent 11603405 Anti-CD3 antibodies and uses thereof
...
Patent Primary Examiner
‌
Zachary S Skelding
Patent abstract

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10465006 Humanized or chimeric CD3 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.